For patients with gout, starting urate-lowering therapy with allopurinol does not appear to lead to an increased risk of developing stage 3 or higher chronic kidney disease (CKD), reports a study in JAMA Internal Medicine.

There is a “dearth of convincing evidence” that lipid-lowering treatment with statin drugs plays any major role in improving outcomes other than cardiovascular disease (CVD), concludes a review and meta-analysis in Annals of Internal Medicine.

Routine catheter replacement does not improve outcomes for hospitalized patients with catheter-associated urinary tract infection (UTI), according to a report in Journal of the American Geriatric Society.

In patients with acute kidney injury (AKI), treatment with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) is associated with a lower risk of death but an increased risk of kidney-related hospitalization, reports a study in JAMA Internal Medicine.

Rituximab appears more effective than tacrolimus in children with corticosteroid-dependent nephrotic syndrome (CDNS), reports a trial in JAMA Pediatrics.

Sulfonylureas are widely used as second-line oral antidiabetic therapy, despite potential cardiotoxicity and hypoglycemia risk. A new UK population-based cohort study suggests that such second-line treatment with sulfonylureas is associated with increased risks of myocardial infarction, death, and severe hypoglycemia. The study was published in the British Medical Journal.


In patients with heart failure and renal impairment, the calcium sensitizer levosimendan is associated with improved kidney function, compared to no improvement with dobutamine, reports a randomized trial in the open-access Journal of the American Heart Association.

The α-adrenergic receptor blocker tamsulosin does not increase passage of small, symptomatic ureteral stones, reports a randomized clinical trial in JAMA Internal Medicine.

The two-phase trial included 512 adults seen in the emergency department with symptomatic ureteral stones. All patients had a symptomatic ureteral stone measuring less than 9 mm in diameter (mean 3.8 mm) on computed tomography. About three-fourths of patents were male and one-fourth were non-white; the mean age was 40.6 years.

A new kidney disease gene panel provides a comprehensive, cost-effective tool for genetic diagnosis of patients with cystic and glomerular inherited kidney diseases, reports a clinical investigation in Kidney International.


A team-based CKD registry improves some clinical measures and care processes for patients in a safety-net primary care setting, reports a trial in the American Journal of Kidney Diseases.